...also had a 2002 deal for adenoviral vector development and manufacturing services with the now-defunct Introgen Therapeutics Inc....

...trials of p53 in Europe for head, neck and hepatocellular cancers. Pending a review of Introgen's...
...also has manufacturing rights in Europe and other markets. Introgen retains North American manufacturing rights. Introgen Therapeutics Inc....

...efficacy or safety in clinical trials. In 2008, FDA refused to file a BLA from Introgen Therapeutics Inc....
...compared to methotrexate in the Phase III T301 trial (see BioCentury, June 2, 2008) . Introgen...
...Calif. Amsterdam Molecular Therapeutics , Amsterdam, the Netherlands Ark Therapeutics Group plc (LSE:AKT), London, U.K. Introgen Therapeutics Inc....

...EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the...
...to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen...
...on its "difficult financial situation." The company filed for Chapter 11 bankruptcy in late 2008. Introgen...

...Inc. (NASDAQ:CEGE) $0.49 53% ImmunoCellular Therapeutics Ltd. (OTCBB:IMUC) $0.37 48% Antigenics Inc. (NASDAQ:AGEN) $0.65 44% Introgen Therapeutics Inc....

...EMEA said Introgen withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to...
...withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to the agency, Introgen...
...FDA refused to file a BLA for Advexin for SCCHN (see BioCentury, Sept. 8, 2008). Introgen Therapeutics Inc....